Abstract: Objective To investigate the therapeutic effect, long term survival and toxicities for advanced NSCLC patients treated with domestic nadaplatin combined with docetaxel.Methods 57 patients with histologically and/or cytologically confirmed advanced NSCLC were treated with domestic nadaplatin 80-100mg/m² and docetaxel 75mg/m² on d1, repeated every 3 weeks.Results The response rate of all the patients were evaluated.There were 4CR, 16 PR, 24 SD and 13 PD in the group, CR add PR was 35.1%, CR add PR and SD was 77.2%.Median time to progression(TTP)was 4.3 months.Median survival duration was 7.4 months.One year survival rate was 34.2%.There was high response in hematological toxicity, non-hematological toxicity were gastrointestinal reactions.Conclusions Domestic nadaplatin combined with docetaxel in second-line treatment for advanced non-small-cell lung cancer is effective, and toxicity is tolerated.

Key words: Nadaplatin, Docetaxel, Second-line treatment, Non-small-cell lung cancer